

Drug resistance interpretation: PR		HIVDB 9.5.1 (2023-11-05)
PI Major Mutations:	None	
PI Accessory Mutations:	None	
PR Other Mutations:	L10V <small>97%</small> <small>seen:47,400</small> • I13V <small>100%</small> <small>seen:43622</small> • G16E <small>99%</small> <small>seen:11,127</small> • E35D <small>97%</small> <small>seen:69,675</small> • M36I <small>100%</small> <small>seen:69,677</small> • R41K <small>99%</small> <small>seen:69,612</small> • H69K <small>91%</small> <small>seen:11,381</small> • K70KR <small>9.40%, 9.40%</small> <small>seen:11,338</small> • L89M <small>100%</small> <small>seen:48,109</small>	
Protease Inhibitors		
atazanavir/r (ATV/r)	Susceptible	
darunavir/r (DRV/r)	Susceptible	
fosamprenavir/r (FPV/r)	Susceptible	
indinavir/r (IDV/r)	Susceptible	
lopinavir/r (LPV/r)	Susceptible	
nelfinavir (NFV)	Susceptible	
saquinavir/r (SQV/r)	Susceptible	
tipranavir/r (TPV/r)	Susceptible	
PR comments		
Other		
<ul style="list-style-type: none"><li>L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.</li></ul>		

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

NRTI Mutations:	None		
NNRTI Mutations:	None		
RT Other Mutations:	K11T 100% <small>seen:19,385</small> • K20R 99% <small>seen:28,540</small> • V21I 99% <small>seen:14,642</small> • V35T 99% <small>seen:22,600</small> • T39N 99% <small>seen:22,366</small> • <b>D86DA</b> 12.42%, 11.24% <small>seen:17,209</small> • <b>D110DG</b> 12.42%, 12.24% <small>seen:26,792</small> • K122E 99% <small>seen:14,963</small> • D123N 99% <small>seen:14,963</small> • S162A 100% <small>seen:13,692</small> • K173L 100% <small>seen:13,623</small> • D177E 97% <small>seen:19,838</small> • V179I 100% <small>seen:19,262</small> • T200A 100% <small>seen:19,538</small> • I202V 100% <small>seen:14,545</small> • Q207A 97% <small>seen:12,696</small> • V245Q 100% <small>seen:21,212</small> • E248D 100% <small>seen:21,314</small> • A272P 100% <small>seen:18,183</small> • I274V 91% <small>seen:18,111</small> • V276VI 9.94%, 11.27% <small>seen:26,996</small> • Q278N 99% <small>seen:14,078</small> • T286A 100% <small>seen:14,272</small> • E291D 99% <small>seen:11,605</small> • I293V 99% <small>seen:11,621</small> • P294T 99% <small>seen:11,628</small> • E312D 100% <small>seen:12,406</small>		
Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	Susceptible
stavudine (D4T)	Susceptible	etravirine (ETR)	Susceptible
didanosine (DDI)	Susceptible	nevirapine (NVP)	Susceptible
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		
RT comments			
Other			
<ul style="list-style-type: none"><li>V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.</li></ul>			

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.